A retrospective review of the real-world experience of the Pegfilgrastim biosimilar (Lapelga®) to the reference biologic (Neulasta®)
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Oncology Pharmacy Practice"
DOI: 10.1177/1078155220974085
Abstract: Introduction Cancer patients receiving myelosuppressive chemotherapy are vulnerable to febrile neutropenia (FN) which contributes to poor treatment outcomes. The use of granulocyte colony-stimulating factors is administered to prevent chemotherapy-induced neutropenia. The introduction of biosimilars has… read more here.
Keywords: reference biologic; review; reference; pegfilgrastim ... See more keywords